Davidson Investment Advisors Has $14.45 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Davidson Investment Advisors increased its holdings in Pfizer Inc. by 45.2%, now owning 596,252 shares worth approximately $14.45 million.
• Pfizer reported a quarterly revenue of $14.65 billion, surpassing analyst expectations, along with an EPS of $0.78 which beat the consensus estimate of $0.58.
• The company declared a quarterly dividend of $0.43 per share, resulting in an annualized dividend yield of 7.1%, with the dividend payout ratio at 91.49%.

Davidson Investment Advisors increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 45.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 596,252 shares of the biopharmaceutical company's stock after purchasing an additional 185,733 shares during the period. Davidson Investment Advisors' holdings in Pfizer were worth $14,453,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the first quarter worth about $27,000. North Capital Inc. acquired a new position in Pfizer in the first quarter worth about $28,000. Bayforest Capital Ltd acquired a new position in Pfizer in the first quarter worth about $28,000. Horizon Financial Services LLC acquired a new position in Pfizer in the first quarter worth about $35,000. Finally, WPG Advisers LLC acquired a new position in Pfizer in the first quarter worth about $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

PFE opened at $24.39 on Thursday. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.82. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company's 50 day simple moving average is $24.89 and its 200-day simple moving average is $24.13. The stock has a market capitalization of $138.69 billion, a P/E ratio of 12.98, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the prior year, the firm earned $0.60 earnings per share. Pfizer's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on PFE shares. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 3rd. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. UBS Group reaffirmed a "neutral" rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Morgan Stanley decreased their price objective on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.